<DOC>
	<DOCNO>NCT00770536</DOCNO>
	<brief_summary>This study 2 part , 2 cohort , open-label , dose escalation/de escalation study AMG 386 combination either pegylated liposomal doxorubicin topotecan subject recurrent ovarian cancer . Up 100 subject enrol receive AMG 386 combination either pegylated liposomal doxorubicin every 4 week ( cohort A ) topotecan weekly day 1 , 8 , 15 28 day dose schedule ( cohort B ) . Subject enrollment assignment either cohort base eligibility investigator 's discretion . It hypothesize AMG 386 , combination chemotherapy regimens : either pegylated liposomal doxorubicin topotecan safe well tolerated subject recurrent ovarian cancer .</brief_summary>
	<brief_title>AMG386 Comb w. Either Pegylated Liposomal Doxorubicin Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR</brief_title>
	<detailed_description>The purpose study evaluate effectiveness safety AMG 386 use pegylated liposomal doxorubicin topotecan subject advance recurrent epithelial ovarian , fallopian tube , primary peritoneal cancer</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histologically cytologically document recurrent invasive epithelial ovarian , fallopian tube , primary peritoneal cancer Subjects must receive least one platinum contain regimen Radiographically document progression per RECIST criterion modification progression CA 125 adopt GCIG subsequent last chemotherapy regimen Subjects may include measurable non measurable disease All scan xrays use document measurable non measurable disease must do within 28 day prior enrollment Female 18 year age old time write informed consent obtain GOG Performance Status 0 1 Left Ventricular Ejection Fraction ( LVEF ) &gt; = institutional low limit normal subject assign cohort A Adequate organ function assess laboratory study ( hematological chemistry ) Life expectancy &gt; = 3 month ( per investigator opinion ) Subjects child bear potential undergone bilateral salpingo oophorectomy sexually active must consent use accepted effective double barrier non hormonal method contraception signing inform consent 6 month last dose study drug Subjects believe high average risk bowel perforation . This include symptom partial complete bowel obstruction , recent ( within 6 month ) history fistula bowel perforation , subject require total parenteral nutrition continuous hydration Previous abdominal /or pelvic external beam radiotherapy Known history central nervous system metastases Subjects history prior malignancy , except : Malignancy treat curative intent know active disease present &gt; = 3 year study day 1 felt low risk recurrence treat physician Adequately treat non melanomatous skin cancer lentigo maligna without evidence disease Adequately treat cervical carcinoma situ without evidence disease Prior myeloablative high dose chemotherapy allogeneic autologous stem cell ( bone marrow ) transplant History arterial deep venous thromboembolism within 12 month prior enrollment Clinically significant cardiac disease within 12 month prior enrollment Prior treatment doxorubicin pegylated liposomal doxorubicin ( cohort A subject ) topotecan ( cohort B subject ) Current within 30 day prior enrollment treatment immune modulators systemic cyclosporine tacrolimus</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>fallopian tube cancer</keyword>
	<keyword>Gynecological Malignancy</keyword>
	<keyword>primary peritoneal cancer predominantly epithelial origin</keyword>
	<keyword>Stage II IV ovarian cancer</keyword>
</DOC>